ElectroCore Inc (ECOR)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$9.210.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · ECOR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
ECOR — earnings miss
Dated 2025-11-05
Results of Operations and Financial Condition. On November 5, 2025, electroCore, Inc. (the “Company”) issued a press release (i) announcing its financial results for the quarter ended September 30, 2025, and (ii) providing updated guidance for the fourth quarter and full year of 2025. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated by reference. Except for information relating to Adjusted EBITDA net loss from operations and its reconciliation to generally ac…
Why it matters: The launch of Quell Relief could boost revenue and expand the product line. This is crucial for growth.
Supportive ifOfficial announcement of Quell Relief launch in Q3 2026.
Worry ifDelay or cancellation of the Quell Relief launch.
Why it matters: Less loss in Adjusted EBITDA shows progress. The company aims for profit by 2027.
Supportive ifAdjusted EBITDA loss improves by at least 25% compared to Q3 2025.
Worry ifAdjusted EBITDA loss improves by less than 25% or worsens.
Why it matters: Stable VA sales growth shows management's plans are working well.
Watch forVA channel prescription sales grow about 11% each year.
Also watch forVA channel prescription sales drop below 11% each year.
Why it matters: Earnings results show how much money the company makes. This matters for how investors feel.
Watch forThe earnings report shows growth and better margins.
Also watch forEarnings report shows declining revenue or margins.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$351 on $10,000 · ±3.5% | How much price usually moves either way. |
| Bad day | $779 loss on $10,000 · 7.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,415 loss on $10,000 · 44.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: If the health care sector grows faster, it can benefit ElectroCore. It indicates a stronger market environment.
Supportive ifHealth care sector growth exceeds 10% year over year.
Worry ifSector growth is under 5%. This shows there are still challenges ahead.
Why it matters: Lower sales and marketing costs mean better efficiency. This leads to higher profit margins.
Supportive ifSales and marketing expenses drop to 54% of revenue by the end of 2027.
Worry ifSales and marketing expenses remain above 54% of revenue by the end of 2027.
Why it matters: Over 30% growth shows management's plans are working. It also shows strong sales.
Supportive ifQ3 revenue growth exceeds 30% year-over-year compared to Q3 2025.
Worry ifQ3 revenue growth is below 30% year-over-year.
Why it matters: Better margins show that costs are managed well. This can help the company grow.
Supportive ifGross profit margin exceeds 87% in Q2 2026.
Worry ifGross profit margin falls below 87% in Q2 2026.
Why it matters: Reducing cash usage is vital for financial health. It impacts the company's ability to fund growth.
Worry ifNet cash usage decreases compared to Q1 2026.
Less concerning ifNet cash usage increases compared to Q1 2026.
Why it matters: High growth in Quell sales shows the market likes the product. Demand is strong.
Supportive ifQuell sales grow by at least 700% year-over-year in Q3 2026.
Worry ifQuell sales growth falls below 700% year-over-year.